Daiichi Sankyo Pharma Development recalls

Daiichi Sankyo Pharma Development has 8 recalls on record with the FDA and USDA, the earliest in 2014 and the latest reported on 6 Aug 2014. The most frequent reason is temperature abuse.

Total recalls8since 2014

Last 12 months0reported

Class I00% of total

Ongoing0latest 6 Aug 2014

Recalls per month, last 24 months

click a bar for that month

0Oct '24 0 0 0Jan '25 0 0 0Apr 0 0 0Jul 0 0 0Oct 0 0 0Jan '26 0 0 0Apr 0 0 0Jul 0 0

Severity split

Class I 0 0%Class II 8 100%Class III 0 0%

Why daiichi sankyo pharma development is recalled

Temperature Abuse8100%

Product types

Blood Pressure Medication788%

By year

20148100%

All daiichi sankyo pharma development recalls, newest first

8 total

Reported	Class	Recall	Company	Reason	Where
6 Aug 2014Drug	CLASS II	Azor Tablets (amlodipine and olmesartan medoxomil) 10 mg*/40 mg recalled	Daiichi Sankyo Pharma Development	Temperature Abuse	Nationwide
6 Aug 2014Drug	CLASS II	Benicar Tablets (olmesartan medoxomil) 40 mg recalled	Daiichi Sankyo Pharma Development	Temperature Abuse	Nationwide
6 Aug 2014Drug	CLASS II	Benicar Tablets (olmesartan medoxomil) 20 mg recalled	Daiichi Sankyo Pharma Development	Temperature Abuse	Nationwide
6 Aug 2014Drug	CLASS II	Tribenzor Tablets (olmesartan medoxomil/amlodipine/hydrochlo recalled	Daiichi Sankyo Pharma Development	Temperature Abuse	Nationwide
6 Aug 2014Drug	CLASS II	Benicar HCT Tablets (olmesartan recalled by Daiichi Sankyo Pharma	Daiichi Sankyo Pharma Development	Temperature Abuse	Nationwide
6 Aug 2014Drug	CLASS II	Benicar HCT Tablets (olmesartan medoxomil recalled	Daiichi Sankyo Pharma Development	Temperature Abuse	Nationwide
6 Aug 2014Drug	CLASS II	Benicar HCT Tablets (olmesartan recalled by Daiichi Sankyo Pharma	Daiichi Sankyo Pharma Development	Temperature Abuse	Nationwide
6 Aug 2014Drug	CLASS II	Welchol Tablets (colesevelam HCl) 625 mg recalled	Daiichi Sankyo Pharma Development	Temperature Abuse	Nationwide

About this list

Records come from FDA enforcement reports and USDA FSIS notices, grouped by normalised name. A company operating under several names may appear more than once.